sur CannaPharmaRx (NASDAQ:CPMD)
CannaPharmaRX Reveals 2026 Growth Strategy amid Global Expansion
CannaPharmaRX, Inc., a key player in cannabis cultivation and export, has announced its strategic plans for 2026. The company is ramping up its international export operations with additional shipments to Israel, while developing new strains such as Black Candyland and Sour Chillz, aimed at the German medical cannabis market.
In 2026, CannaPharmaRX intends to increase its European export capacity by constructing new cultivation and drying facilities, compliant with EU-GMP standards. These investments aim to support expanded supply to Germany and other European markets.
The previously imposed trade restrictions by the British Columbia Securities Commission have been lifted, facilitating these expansion efforts. CannaPharmaRX remains cautious, highlighting the forward-looking nature of their growth projections.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CannaPharmaRx